Skip to main content
SpringerLink
Log in

Cutaneous Lupus

  • Chapter
  • First Online:
Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology

  • 595 Accesses

Abstract

Lupus erythematosus (LE) can affect the skin, the internal organs, or both. In this chapter we review the cutaneous findings specific to LE as well as the nonspecific skin findings that may be associated with systemic LE. Cutaneous disease represents the second most common presentation in systemic lupus erythematosus (SLE), and as such, dermatologists play an important role in the evaluation and diagnosis for these patients by correlating clinical findings with those demonstrated on skin biopsy if needed, and by undertaking initial risk assessment for systemic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jarukitsopa S, Hoganson DD, Crowson CS. Epidemiology of systemic lupus erythematosus and cutaneous lupus in a predominantly white population in the United States. Arthritis Care Res Hoboken; 2015.

    Google Scholar 

  2. Durosaro O, et al. Incidence of cutaneous lupus erythematosus, : a population-based study. Arch Dermatol. 2009;145:249–53.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Piette EW, Foering KP, Chang AY. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012;148:317–22.

    Article  PubMed  Google Scholar 

  4. Moghadam-Kia S, Chilek K, Gaines E. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009;145:255–60.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–5.

    Article  CAS  PubMed  Google Scholar 

  6. Kuhn A, et al. Clinical manifestations of cutaneous lupus erythematosus. Dermatol Ges. 2007;5:1124–37.

    Article  Google Scholar 

  7. Lipsker D. The need to revisit the nosology of cutaneous lupus erythematosus: the current terminology and morphologic classification of cutaneous LE: difficult, incomplete and not always applicable. Lupus. 2010;19:1047–9.

    Article  CAS  PubMed  Google Scholar 

  8. Schultz HY, et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE). Dermatology. 2015;135:7–12.

    CAS  Google Scholar 

  9. Merola JF, Nyberg F, Furukawa F. Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire. Lupus Sci Med. 2015;2:e000085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zecevic RD, et al. Skin lesions-an indicator of disease activity in systemic lupus erythematosus? Lupus. 2001;10:364.

    Article  CAS  PubMed  Google Scholar 

  11. Tan EM, Cohen AS, Fries JF. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271.

    Article  CAS  PubMed  Google Scholar 

  12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.

    Article  CAS  PubMed  Google Scholar 

  13. Tan EM. Criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1984;25:53.

    Google Scholar 

  14. Albrecht JA, Braverman IM, Callen JP. Dermatology position paper on the revision of the ACR criteria for SLE. Lupus. 2004;13:839.

    Article  CAS  PubMed  Google Scholar 

  15. Petri M, Orbai AM, Alarcon GS. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ighe A, et al. Application of the systemic lupus interna tional collaborating clinics classification criteria on a Regional Swedish systemic lupus erythematosus register. Arthritis Res Ther. 2015;17:3.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ines L, Silva C, Galindo M. Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus american college of rheumatology criteria. Arthritis Care Res Hoboken; 2015.

    Google Scholar 

  18. Dey-Rao R, Sinha AA. Genome-wide transcriptional profiling of chronic cutaneous lupus erythematosus (CCLE) peripheral blood identifies systemic alterations relevant to the skin manifestation. Genomics. 2015;105:90–100.

    Article  CAS  PubMed  Google Scholar 

  19. Lee LA, et al. Autoantibodies of neonatal lupus erythematosus. Dermatol Antibodydependent cellular cytotoxicity and skin disease. J Invest Dermatol. 1985;85(suppl 165):963–6.

    Google Scholar 

  20. Millard TP, Kondeatis E, Cox A. A candidate gene analysis of three related photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. Br J Dermatol. 2001;145:229.

    Article  CAS  PubMed  Google Scholar 

  21. Fischer GF, et al. Association between chronic cutaneous lupus erythematosus and HLA class II alleles. Hum Immunol. 1994;41:280–4.

    Article  CAS  PubMed  Google Scholar 

  22. Werth VP, et al. Association of a promoter polymorphism of TNFalpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol. 2000;115:726–30.

    Article  CAS  PubMed  Google Scholar 

  23. Osmola A, et al. Genetic background of cutaneous forms of lupus erythematosus: update on current evidence. J Appl Genet. 2004;45:77–86.

    PubMed  Google Scholar 

  24. Jarvinen TM, et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS One. 2010;5:14212.

    Article  Google Scholar 

  25. Kim-Howard X, Maiti AK, Anaya JM. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis. 2010;69:1329–32.

    Article  PubMed  Google Scholar 

  26. Sanchez E, Nadig A, Richardson BC. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1752–7.

    Article  CAS  PubMed  Google Scholar 

  27. Kunz M, Konig IR, Schillert A. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp Dermatol. 2015;24(7):510–5.

    Article  CAS  PubMed  Google Scholar 

  28. Jarvinen TM, Hellquist A, Koskenmies S. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol. 2010;19:123–31.

    Article  CAS  PubMed  Google Scholar 

  29. Pickering MC, et al. Ultraviolet-radiation-induced keratinocyte apoptosis in C1q-deficient mice. J Invest Dermatol. 2001;117:52.

    Article  CAS  PubMed  Google Scholar 

  30. Nousari HC, et al. Generalized lupus panniculitis and antiphospholipid syndrome in a patient without complement deficiency. Ped Dermatol. 1999;16:273.

    Article  CAS  Google Scholar 

  31. Lee-Kirsch MA, Gong M, Schulz H. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet. 2006;79:731.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sanders CJ, et al. Photosensitivity in patients with lupus erythematosus:a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br J Dermatol. 2003;149:131–7.

    Article  CAS  PubMed  Google Scholar 

  33. Kuhn A, et al. Photoprovocation in cutaneous lupus erythematosus: study evaluating a standardized protocol. J Invest Dermatol. 2011;131:1622–30.

    Article  CAS  PubMed  Google Scholar 

  34. Rosenbaum M, Billet S, Patel P. Failure of physiologic doses of pure UVB or UVA to induce lesions in photosensitive lupus erythematosus: implications for phototesting and sunblocking strategies. Photodermatol Photoimmunol Photomed. 2006;22:290.

    Article  Google Scholar 

  35. Furukawa F, et al. Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol. 1990;94:77.

    Article  CAS  PubMed  Google Scholar 

  36. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targets in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179:1317.

    Article  CAS  PubMed  Google Scholar 

  37. Kuhn A, Herrmann M, Kleber S. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. see comment. Arthritis Rheum. 2007;54:939.

    Article  Google Scholar 

  38. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology. 2002;205:395–406.

    Article  CAS  PubMed  Google Scholar 

  39. Kreuter A, et al. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. Acad Dermatol. 2011;65:125–33.

    Article  CAS  Google Scholar 

  40. Villanueva E, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus; 2011. p. 538–52.

    Google Scholar 

  41. Popovic K, Ek M, Espinosa A. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erthematosus. Arthritis Rheum. 2005;52:3639.

    Article  CAS  PubMed  Google Scholar 

  42. Chang LM, Maheshwari P, Werth S. Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis. J Histochem Cytochem. 2011;59:336–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Jabbari A, et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol. 2014;134:87–95.

    Article  CAS  PubMed  Google Scholar 

  44. Franz B, Fritzsching B, Riehl A. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum. 2007;56:1910–20.

    Article  CAS  PubMed  Google Scholar 

  45. Wong D, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012;7:29161.

    Article  Google Scholar 

  46. Braunstein I, et al. The interferon-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score. Br J Dermatol. 2012;166:971–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wenzel J, et al. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol. 2007;157:752–7.

    Article  CAS  PubMed  Google Scholar 

  48. Gambichler T, et al. Cytokine and chemokine ligand expression in cutaneous lupus erythematosus. Eur J Dermatol. 2012;22:319–23.

    Article  CAS  PubMed  Google Scholar 

  49. Zahn S, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131:133–40.

    Article  CAS  PubMed  Google Scholar 

  50. Meller S, Winterberg F, Gilliet M. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52:1504–16.

    Article  CAS  PubMed  Google Scholar 

  51. Werth VP, Zhang W. Wavelength-specific synergy between ultraviolet radiation and interleukin-1 alpha in the regulation of matrix-related genes: mechanistic role for tumor necrosis factor-alpha. J Invest Dermatol. 1999;113:196–201.

    Article  CAS  PubMed  Google Scholar 

  52. Nabatian AS, et al. TNFα release in peripheral blood mononuclear cells of cutaneous lupus & dermatomyositis patients. Arthritis Res Ther. 2012;4:R1.

    Article  Google Scholar 

  53. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006;24:348–62.

    Article  PubMed  Google Scholar 

  54. Gronhagen CM, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164:1335–41.

    Article  CAS  PubMed  Google Scholar 

  55. Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol. 1994;21:1665–9.

    CAS  PubMed  Google Scholar 

  56. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115(12):1409–15.

    Article  CAS  PubMed  Google Scholar 

  57. Evans KG, Heymann WR. Paraneoplastic subacute cutaneous lupus erythematosus: an underrecognized entity. Cutis. 2013;91:25–9.

    PubMed  Google Scholar 

  58. Chang AY, et al. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol. 2013;149:104–6.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Verma SM, et al. The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol. 2014;170:315–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Sampaio MC, et al. dos Discoid lupus erythematosus in children-a retrospective study of 34 patients. Pediatr Dermatol. 2008;25:163–7.

    Article  PubMed  Google Scholar 

  61. Vera-Recabarren MA, et al. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol. 2010;162:91–101.

    Article  CAS  PubMed  Google Scholar 

  62. Parish LC, Kennedy RJ, Hurley J. Palmar lesions in lupus erythematosus. Arch Dermatol. 1967;96:273–6.

    Article  CAS  PubMed  Google Scholar 

  63. Tao J, et al. Squamous cell carcinoma complicating discoid lupus erythematosus in Chinese patients: review of the literature. Acad Dermatol. 2012;66:695.

    Article  Google Scholar 

  64. Prystowsky SD, Gilliam JN. Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch Dermatol. 1975;111:1448–52.

    Article  CAS  PubMed  Google Scholar 

  65. Gysel D, et al. Van de Waard- Childhood discoid lupus erythematosus: report of five new cases and review of the literature. Acad Dermatol Venereol. 2002;16:143–7.

    Article  Google Scholar 

  66. Moises-Alfaro C, et al. Discoid lupus erythematosus in children: clinical, histopathologic, and follow-up features in 27 cases. Pediatr Dermatol. 2003;20:103–7.

    Article  PubMed  Google Scholar 

  67. Magro CM, et al. Atypical lymphocytic lobular panniculitis: a clonal subcutaneous T-cell dyscrasia. J Cutan Pathol. 2008;35:947–54.

    Article  PubMed  Google Scholar 

  68. Viguier M, Pinquier L, Cavelier-Balloy B. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore). 2001;80:180–8.

    Article  CAS  Google Scholar 

  69. Rivera TL, Izmirly PM, Birnbaum BK. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009;68:828–35.

    Article  CAS  PubMed  Google Scholar 

  70. Buyon JP, et al. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin North Am. 2010;31:299–313.

    Article  Google Scholar 

  71. Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics. 2002;109:E11.

    Article  PubMed  Google Scholar 

  72. Buyon JP. Neonatal lupus and autoantibodies reactive with SSA/Ro-SSB/La. Scand J Rheumatol Suppl. 1998;107:23–30.

    Article  CAS  PubMed  Google Scholar 

  73. Hall RP, et al. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med. 1982;97:165–70.

    Article  CAS  PubMed  Google Scholar 

  74. Gammon WR, et al. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993;100:28S–34.

    Article  CAS  PubMed  Google Scholar 

  75. Ting W, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13:941–50.

    Article  CAS  PubMed  Google Scholar 

  76. Torchia D, et al. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am Acad Dermatol. 2012;67:417–21.

    Article  PubMed  Google Scholar 

  77. Ziemer M, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575–600.

    Article  CAS  PubMed  Google Scholar 

  78. Rowell NR, et al. Lupus erythematosus and erythema multiforme-like lesions. A syndrome with characteristic immunological abnormalities. Arch Dermatol. 1963;83:176–80.

    Article  Google Scholar 

  79. Zeitouni NC, et al. Redefining Rowell’s syndrome. Br J Dermatol. 2000;142:343–6.

    Article  CAS  PubMed  Google Scholar 

  80. Alarcon-Segovia D, Cetina JA. Lupus hair. Am J Med Sci. 1974;267:241–2.

    Article  CAS  PubMed  Google Scholar 

  81. Fabre VC, et al. Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol. 1991;127:1006–11.

    Article  CAS  PubMed  Google Scholar 

  82. David-Bajar KM, Davis BM. Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus. Lupus. 1997;6:145–57.

    Article  CAS  PubMed  Google Scholar 

  83. Li PH, Wong WH, Lee TL. Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. Rheumatology (Oxford). 2013;52:337–45.

    Article  Google Scholar 

  84. Lee LA, et al. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol. 1994;130:1262.

    Article  CAS  PubMed  Google Scholar 

  85. Kuhn A, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol. 2001;45:86–95.

    Article  CAS  PubMed  Google Scholar 

  86. Kuhn A, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2010;64:37–48.

    Article  Google Scholar 

  87. Klein RS, et al. Analysis of compact fluorescent lights for use by patients with photosensitive conditions. Photochem Photobiol. 2009;85(4):1004–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Sayre RM, Dowdy JC, Poh-Fitzpatrick M. Dermatological risk of indoor ultraviolet exposure from contemporary lighting sources. Photochem Photobiol. 2004;80:47–51.

    Article  CAS  PubMed  Google Scholar 

  89. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000;42:983–7.

    Article  CAS  PubMed  Google Scholar 

  90. Wahie S, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131:1981–6.

    Article  CAS  PubMed  Google Scholar 

  91. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;5:CD002954.

    Google Scholar 

  92. Roenigk HH, et al. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980;25:281–5.

    PubMed  Google Scholar 

  93. Kuhn A, et al. Efficacy of tacrolimus 0.1 ointment in cutaneous lupus erythematosus a multicenter randomized doubleblind vehiclecontrolled trial. Acad Dermatol. 2011;65:54–64.

    Article  CAS  Google Scholar 

  94. Tzung TY, et al. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus a randomized doubleblind bilateral comparison study. Br J Dermatol. 2007;156:191–2.

    Article  CAS  PubMed  Google Scholar 

  95. Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010;28:52–6.

    Article  PubMed  Google Scholar 

  96. Erceg A, et al. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus The Canadian Hydroxychloroquine Study Group 3241504. 1991;60:626–32.

    Article  Google Scholar 

  97. James JA, Kim-Howard XR, Bruner BF. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16:401–9.

    Article  CAS  PubMed  Google Scholar 

  98. Chang AY, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147:1261–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Frances C, Cosnes A, Duhaut P. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148:479–84.

    Article  CAS  PubMed  Google Scholar 

  100. Levy GD, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40:1482–6.

    Article  CAS  PubMed  Google Scholar 

  101. Marmor MF, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–22.

    Article  PubMed  Google Scholar 

  102. Ward WQ, et al. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol. 1985;12:863–5.

    Article  CAS  PubMed  Google Scholar 

  103. Schmid I, et al. Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine. Blut. 1990;61:52–4.

    Article  CAS  PubMed  Google Scholar 

  104. Siddiqui AK, et al. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest. 2007;131:588–90.

    Article  CAS  PubMed  Google Scholar 

  105. Creel N, Werth VP. Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus. J Drugs Dermatol. 2005;4:225.

    PubMed  Google Scholar 

  106. Bili A, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol. 2011;17(3):115–20.

    Article  PubMed  Google Scholar 

  107. Wasko MC, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187–93.

    Article  CAS  PubMed  Google Scholar 

  108. Chen YM, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54(7):1244–9.

    Article  CAS  Google Scholar 

  109. Mercer E, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012;14(3):R135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Wahie S, Meggitt SJ. Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus. Br J Dermatol. 2013;169:653–9.

    Article  CAS  PubMed  Google Scholar 

  111. Kuhn A, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2002;46:600–3.

    Article  PubMed  Google Scholar 

  112. Bohm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology. 1997;194:307–8.

    Article  CAS  PubMed  Google Scholar 

  113. Malcangi G, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus. 2003;12:63–6.

    Article  CAS  PubMed  Google Scholar 

  114. Wenzel J, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153:157–62.

    Article  CAS  PubMed  Google Scholar 

  115. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18:59–62.

    Article  CAS  PubMed  Google Scholar 

  116. Cetkovska P, Pizinger K. Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol. 2006;45:320–2.

    Article  PubMed  Google Scholar 

  117. Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol. 2002;138:1616–8.

    Article  PubMed  Google Scholar 

  118. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol. 2001;137:235–6.

    CAS  PubMed  Google Scholar 

  119. Kreuter A, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156:1321–7.

    Article  CAS  PubMed  Google Scholar 

  120. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol. 2001;45:142–4.

    Article  CAS  PubMed  Google Scholar 

  121. Schanz S, et al. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol. 2002;147:174–8.

    Article  CAS  PubMed  Google Scholar 

  122. Gammon B, et al. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. Acad Dermatol. 2011;65:717–21.

    Article  CAS  Google Scholar 

  123. Ginzler EM, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010;62:211–21.

    Article  CAS  PubMed  Google Scholar 

  124. Pisoni CN, Obermoser G, Cuadrado MJ. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol. 2005;23:393–6.

    CAS  PubMed  Google Scholar 

  125. Swaak AJ, et al. Statius Azathioprine in the treatment of systemic lupus erythematosus. A threeyear prospective study. Clin Rheumatol. 1984;3:285–91.

    Article  CAS  PubMed  Google Scholar 

  126. Ashinoff R, et al. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol. 1988;19:961–5.

    Article  CAS  PubMed  Google Scholar 

  127. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol. 1985;121:1323–5.

    Article  CAS  PubMed  Google Scholar 

  128. Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol. 1986;122:376–7.

    Article  CAS  PubMed  Google Scholar 

  129. Nero P, Rahman A, Isenberg DA. Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? Ann Rheum Dis. 2004;63:325–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Lakshminarayanan S, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28(1):102–8.

    CAS  PubMed  Google Scholar 

  131. Cohen-Cline H, et al. Use of interactive voice response to improve colorectal cancer screening. Med Care. 2014;52(6):496–9.

    Article  PubMed  Google Scholar 

  132. Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol. 1982;106(1):105–6.

    Article  CAS  PubMed  Google Scholar 

  133. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. 1986;172(4):214–7.

    Article  CAS  PubMed  Google Scholar 

  134. Prussick R, et al. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol. 1992;128(2):210–3.

    Article  CAS  PubMed  Google Scholar 

  135. Coleman MD, et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol. 1992;34(3):244–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Cortés-Hernández J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166(3):616–23.

    Article  PubMed  Google Scholar 

  137. Stevens RJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol. 1997;36(3):353–9.

    Article  CAS  PubMed  Google Scholar 

  138. Burrows NP, et al. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol. 1991;125:62–7.

    Article  CAS  PubMed  Google Scholar 

  139. Pelle MT, Werth VP. Thalidomide in cutaneous lupus erythematosus. Am J Clin Dermatol. 2003;4(6):379–87.

    Article  PubMed  Google Scholar 

  140. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98–104.

    Article  PubMed  Google Scholar 

  141. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991;24(1):49–52.

    Article  CAS  PubMed  Google Scholar 

  142. Ruzicka T, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):513–8.

    Article  CAS  PubMed  Google Scholar 

  143. Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol. 1990;29(8):587–90.

    Article  CAS  PubMed  Google Scholar 

  144. Man A, et al. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology (Oxford). 2015;54(8):1464–71.

    Article  Google Scholar 

  145. Ky C, et al. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study. Dermatol Reports. 2015;7(1):5804.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Strauss RM, et al. Good response of linear scleroderma in a child to ciclosporin. Br J Dermatol. 2004;150(4):790–2.

    Article  CAS  PubMed  Google Scholar 

  147. De Pità O, et al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997;6(4):415–7.

    Article  PubMed  Google Scholar 

  148. Manzi S, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8.

    Article  CAS  PubMed  Google Scholar 

  149. Chaudhry SI, Murphy LA, White IR. Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis? Clin Exp Dermatol. 2005;30(6):655–8.

    Article  CAS  PubMed  Google Scholar 

  150. Jasim ZF, Walsh MY, Armstrong DK. Subacute lupus erythematosus-like rash associated with oesophageal adenocarcinoma in situ. Clin Exp Dermatol. 2007;32(4):443–5.

    Article  CAS  PubMed  Google Scholar 

  151. Shaheen B, Milne G, Shaffrali F. Subacute cutaneous lupus erythematosus associated with breast carcinoma. Clin Exp Dermatol. 2009;34(7):e480–1.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA

    Lisa Pappas-Taffer & Victoria P. Werth

  2. Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA

    Lisa Pappas-Taffer & Victoria P. Werth

  3. University of Pennsylvania, Internal Medicine, Division of Rheumatology, Philadelphia, PA, USA

    Tania C. Gonzalez-Rivera

Authors
  1. Lisa Pappas-Taffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tania C. Gonzalez-Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Victoria P. Werth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victoria P. Werth .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, Hempstead, NY, USA

    Amit Garg

  2. Department of Dermatology Department of Medicine Division of Rheumatology Inflammation and Immunity, Brigham and Women’s Hospital Harvard Medical School, Boston, MA, USA

    Joseph F. Merola

  3. Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, Hempstead, NY, USA

    Laura Fitzpatrick

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pappas-Taffer, L., Gonzalez-Rivera, T.C., Werth, V.P. (2022). Cutaneous Lupus. In: Garg, A., Merola, J.F., Fitzpatrick, L. (eds) Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology. Springer, Cham. https://doi.org/10.1007/978-3-319-18446-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18446-3_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18445-6

  • Online ISBN: 978-3-319-18446-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation